RECURRENT NON-SMALL CELL LUNG CARCINOMA
Clinical trials for RECURRENT NON-SMALL CELL LUNG CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT NON-SMALL CELL LUNG CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT NON-SMALL CELL LUNG CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo battle for lung cancer survival
Disease control OngoingThis study is for people with advanced or recurrent non-small cell lung cancer that has a specific genetic change (EGFR mutation). It compares two treatment approaches: taking a pill called afatinib alone, or taking afatinib plus receiving an IV drug called cetuximab. The main go…
Matched conditions: RECURRENT NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Apr 01, 2026 22:11 UTC
-
New drug cocktail tested in fight against tough cancers
Disease control OngoingThis early-stage study is testing the safety and best dose of a new drug called sEphB4-HSA when given alongside standard chemotherapy. It involves about 61 people with specific advanced or spreading cancers, including pancreatic, lung, and head/neck cancers, that have stopped res…
Matched conditions: RECURRENT NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Radiation boost after chemo tested to keep lung cancer at bay
Disease control OngoingThis trial is for people with advanced non-small cell lung cancer that has spread to only a few other body sites. It tests whether adding targeted radiation or surgery to the areas where cancer remains, on top of ongoing maintenance chemotherapy, helps control the cancer better a…
Matched conditions: RECURRENT NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Mar 13, 2026 15:06 UTC